keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/28725583/positron-emission-tomography-pet-in-primary-prostate-cancer-staging-and-risk-assessment
#1
REVIEW
Sandra Bednarova, Maria L Lindenberg, Maria Vinsensia, Chiara Zuiani, Peter L Choyke, Baris Turkbey
Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, identification of biochemical recurrence (BCR) and evaluation of metastatic disease. Here, we focus on primary disease and local staging. To date, magnetic resonance imaging (MRI) has proven superior to PET in the imaging of primary PCa...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28723518/mid-term-outcomes-following-salvage-lymph-node-dissection-for-prostate-cancer-nodal-recurrence-status-post-radical-prostatectomy
#2
Fabio Zattoni, Avinash Nehra, Christopher R Murphy, Laureano Rangel, Lance Mynderse, Val Lowe, Eugene Kwon, R Jeffrey Karnes
BACKGROUND: Patients with oligometastatic prostate cancer lymph node recurrence can be treated with many options including salvage lymph node dissection (sLND). OBJECTIVE: Evaluation of outcomes of sLND and identification of clinicopathologic features in predicting further biochemical and radiological relapse after sLND for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Between November 1, 2009 and March 31, 2015, 117 patients with biochemical recurrence (BCR) after radical prostatectomy (RP) underwent sLND by a single surgeon after a standardized 11C-choline positron emission tomography/computed tomography...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28721304/imaging-features-of-paget-s-disease-on-11-c-choline-pet-ct
#3
Cameron E Leitch, Ajit H Goenka, Benjamin M Howe, Stephen M Broski
The purpose of this study was to investigate the appearance of Paget's disease (PD) on (11)C choline PET/CT and correlate these findings to serum alkaline phosphatase (ALP) level and skeletal scintigraphy. With IRB approval, our institutional (11)C choline PET/CT database (9/2005-6/2015) was searched for patients with PD. Site of osseous involvement, CT appearance, and multiple semi-quantitative measures were measured and correlated with ALP and degree of uptake on bone scan. Our search identified 10 males (mean age 79...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28719746/structure-activity-study-of-ghrelin-1-8-resulting-in-high-affinity-fluorine-bearing-ligands-for-the-ghrelin-receptor
#4
Carlie L Charron, Jin-Qiang Hou, Mark S McFarland, Savita Dhanvantari, Michael S Kovacs, Leonard G Luyt
The ghrelin receptor, also known as the growth hormone secretagogue receptor 1a (GHS-R1a), is a G-protein coupled receptor that is differentially expressed in healthy tissue and several cancers, including prostate, testicular, and ovarian. Selectively targeting the ghrelin receptor using fluorine-18 tagged entities would allow localization and visualization of ghrelin receptor expressing carcinomas using PET imaging. The endogenous ligand ghrelin, a 28 amino acid peptide with 3.1 nM affinity, has poor in vivo stability...
July 18, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28719629/multiparametric-11c-acetate-positron-emission-tomography-magnetic-resonance-imaging-in-the-assessment-and-staging-of-prostate-cancer
#5
Stephan H Polanec, Piotr Andrzejewski, Pascal A T Baltzer, Thomas H Helbich, Alexander Stiglbauer, Dietmar Georg, Georgios Karanikas, Martin Susani, Wolfgang Wadsak, Markus Margreiter, Markus Mitterhauser, Peter Brader, Katja Pinker
BACKGROUND: The aim of this study was to evaluate whether MP [11C]Acetate PET-MRI enables an accurate differentiation of benign and malignant prostate tumors as well as local and distant staging. MATERIALS AND METHODS: Fifty-six consecutive patients fulfilling the following criteria were included in this IRB-approved prospective study: elevated PSA levels or suspicious findings at digital rectal examination or TRUS; and histopathological verification. All patients underwent MP [11C]Acetate PET-MRI of the prostate performed on separate scanners with PET/CT using [11C]Acetate and 3T MP MR imaging...
2017: PloS One
https://www.readbyqxmd.com/read/28719451/pancreatic-ductal-adenocarcinoma-with-high-radiotracer-uptake-in-68ga-prostate-specific-membrane-antigen-pet-ct
#6
Samine Sahbai, Petra Rieping, Christina Pfannenberg, Christian la Fougère, Matthias Reimold
Prostate-specific membrane antigen imaging with PET/CT is increasingly used in prostate cancer and was shown to have a high diagnostic performance. We report a clinical case of a 67-year-old man with previous history of operated prostate cancer and increasing prostate-specific antigen blood level. Ga-HBED-CC prostate-specific membrane antigen PET/CT imaging was indicated for the assessment of local recurrence and lymph node metastases of prostate cancer. In addition, a soft tissue mass in the body of the pancreas with high radiotracer uptake was detected...
July 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28719450/combination-of-177lu-psma-617-and-external-radiotherapy-for-the-treatment-of-cerebral-metastases-in-patients-with-castration-resistant-metastatic-prostate-cancer
#7
Xiao Wei, Carl Schlenkhoff, Bettina Schwarz, Markus Essler, Hojjat Ahmadzadehfar
Two castration-resistant prostate cancer patients, both with cerebral and visceral and lymphatic metastases, received multiple cycles of Lu-PSMA-617 treatments. The prognosis of both cases is dependent on brain metastases. Between Lu-PSMA-617 treatment cycles, local radiotherapy was also applied to the brain metastases. Prior to the combined therapy, all systemic metastases, including cerebral lesions, showed PSMA expression using Ga-PSMA PET/CT. Under the combined therapy, all the metastases, particularly the cerebral lesions, showed significant regression in size and PSMA expression over time...
July 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28719448/biopsy-proven-diffuse-mediastinal-prostate-cancer-metastases-negative-on-18f-fluorocholine-diagnosed-on-68ga-psma-and-18f-psma-pet-ct
#8
Guillaume Chaussé, Tamim Niazi, Gad Solomon Abikhzer, Stephan Michael Probst
A 72-year-old man with prostate cancer (stage T3b, Gleason score 7) treated by radical prostatectomy was found to have biochemical failure (prostate-specific antigen 8.5 ng/mL) and a suspicious growing nodularity at the left prostate bed on MRI. F-fluorocholine PET/CT failed to demonstrate any site of uptake suggestive of malignancy. A bone scan did exclude bone metastases. Ga-PSMA PET/CT revealed various positive lymph nodes in the supraclavicular, mediastinal, and hilar regions. This was confirmed on F-DCFPyl PET/CT, with the addition of a suspicious right axillary lymph node...
July 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28719112/defining-the-clinical-utility-of-psma-targeted-pet-imaging-of-prostate-cancer
#9
EDITORIAL
Michael A Gorin, Martin G Pomper, Kenneth J Pienta, Steven P Rowe
No abstract text is available yet for this article.
August 2017: BJU International
https://www.readbyqxmd.com/read/28718164/advances-in-imaging-in-prostate-and-bladder-cancer
#10
REVIEW
Abhishek Srivastava, Laura M Douglass, Victoria Chernyak, Kara L Watts
Recent advancements in urologic imaging techniques aim to improve the initial detection of urologic malignancies and subsequent recurrence and to more accurately stage disease. This allows the urologist to make better informed treatment decisions. In particular, exciting advances in the imaging of prostate cancer and bladder cancer have recently emerged including the use of dynamic, functional imaging with MRI and PET. In this review, we will explore these imaging modalities, in addition to new sonography techniques and CT, and how they hope to improve the diagnosis and management of prostate and bladder cancer...
September 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28717648/response-detection-of-castrate-resistant-prostate-cancer-to-clinically-utilised-and-novel-treatments-by-monitoring-phospholipid-metabolism
#11
Tim A D Smith, Su M Phyu, Kholoud S Alzyoud, Chih-Chung Tseng
Androgen receptor (AR) activation is the primary driving factor in prostate cancer which is initially responsive to castration but then becomes resistant (castration-resistant prostate cancer (CRPC)). CRPC cells still retain the functioning AR which can be targeted by other therapies. A recent promising development is the use of inhibitors (Epi-1) of protein-protein interaction to inhibit AR-activated signalling. Translating novel therapies into the clinic requires sensitive early response indicators. Here potential response markers are explored...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28716214/early-68-ga-psma-pet-mri-acquisition-assessment-of-lesion-detectability-and-pet-metrics-in-patients-with-prostate-cancer-undergoing-same-day-late-pet-ct
#12
L Domachevsky, H Bernstine, N Goldberg, M Nidam, D Stern, J Sosna, D Groshar
AIM: To compare lesion detectability and positron-emission tomography (PET) metric measurements between early-PET/magnetic resonance imaging (MRI) acquisition and same-day PET/computed tomography (CT). MATERIALS AND METHODS: The study was approved by the institutional review board and written informed consent was obtained from all patients. Twenty-one patients underwent non-time-of-flight (TOF) PET/MRI immediately following (68)GA-prostate-specific membrane antigen (PSMA) tracer injection in two steps: firstly, early prostate PET/MRI (pPET/MRI) and early whole-body (WB) PET/MRI (wbPET/MR) followed by WB TOF PET/CT (wbPET/CT)...
July 14, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28715042/-diagnostic-significance-of-multiparametric-mri-combined-with-us-fusion-guided-biopsy-of-the-prostate-in-patients-with-increased-psa-levels-and-negative-standard-biopsy-results-to-detect-significant-prostate-cancer-correlation-with-the-gleason-score-korrelation
#13
Manuela Hoffmann, Manuela A Hoffmann, Helmut J Wieler, Frank M Jakobs, Kasra Taymoorian, Arnd Gerhards, Matthias Miederer, Mathias Schreckenberger
AIMS: To increase diagnostic precision and to reduce overtreatment of low-risk malignant disease, multiparametric MRI (mpMRI) combined with ultrasound (US) fusion guided biopsy of the prostate were performed. METHODS: In 99 male patients with increased PSA plasma levels and previous negative standard biopsy procedures, mpMRI was carried out followed by US fusion guided perineal biopsy. PI-RADS-Data (PS) of mpMRI and histopathological Gleason score (GS) were categorized and statistically compared...
July 17, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28713796/multimodal-imaging-in-focal-therapy-planning-and-assessment-in-primary-prostate-cancer
#14
Hossein Jadvar
PURPOSE: There is increasing interest in focal therapy (male lumpectomy) of localized low-intermediate risk prostate cancer. Focal therapy is typically associated with low morbidity and provides the possibility of retreatment. Imaging is pivotal in stratification of men with localized prostate cancer for active surveillance, focal therapy or radical intervention. This article provides a concise review of focal therapy and the evolving role of imaging in this clinical setting. METHODS: We performed a narrative and critical literature review by searching PubMed/Medline database from January 1997 to January 2017 for articles in the English language and the use of search keywords "focal therapy", "prostate cancer", and "imaging"...
June 2017: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28711565/new-aspects-of-molecular-imaging-in-prostate-cancer
#15
Francesco Ceci, Paolo Castellucci, Juliano J Cerci, Stefano Fanti
Nowadays several new imaging modalities are available for investigating prostate cancer (PCa) such as magnet resonance imaging (MRI) in the form of whole body MRI and pelvic multiparametric MRI and positron emission tomography (PET) using choline as radiotracers. Nevertheless, these modalities proved sub-optimal accuracy for detecting PCa metastases, particularly in the recurrence setting. A new molecular probe targeting the prostate specific membrane antigen (PSMA) has been recently developed for PET imaging...
July 12, 2017: Methods: a Companion to Methods in Enzymology
https://www.readbyqxmd.com/read/28709149/uptake-of-psma-ligands-in-normal-tissues-is-dependent-on-tumor-load-in-patients-with-prostate-cancer
#16
Florian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, Stefan Kürpig, Elisabeth Eppard, Charalambos Kotsikopoulos, Nikolaos Liakos, Ralph A Bundschuh, Holger Strunk, Markus Essler
Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load. RESULTS: In patients with high tumor load, SUVmean was reduced to 61.5% in the lacrimal glands, to 56.6% in the parotid glands, to 63.7% in the submandibular glands, to 61.3% in the sublingual glands and to 55.4% in the kidneys (p < 0...
July 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28707038/-68-ga-psma-hbed-cc-uptake-in-osteolytic-osteoblastic-and-bone-marrow-metastases-of-prostate-cancer-patients
#17
Jan-Carlo Janssen, Nadine Woythal, Sebastian Meißner, Vikas Prasad, Winfried Brenner, Gerd Diederichs, Bernd Hamm, Marcus R Makowski
PURPOSE: The aim of this study was to evaluate potential differences in "Glu-NH-CO-NH-Lys" radio-labeled with [(68)Ga]gallium N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N-diacetic acid ([(68)Ga]PSMA-HBED-CC) uptake in osteolytic, osteoblastic, mixed, and bone marrow metastases in prostate cancer (PC) patients. PROCEDURES: This retrospective study was approved by the local ethics committee. Patients who received [(68)Ga]PSMA-HBED-CC positron emission tomography/computed tomography ([(68)Ga]PSMA-PET/CT) with at least one positive bone metastasis were included in this study...
July 13, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28704341/uptake-of-the-prostate-specific-membrane-antigen-targeted-pet-radiotracer-18f-dcfpyl-in-elastofibroma-dorsi
#18
Michael A Gorin, Wael Marashdeh, Ashley E Ross, Mohammad E Allaf, Kenneth J Pienta, Martin G Pomper, Steven P Rowe
OBJECTIVE: PET imaging using radiotracers that target prostate-specific membrane antigen (PSMA) are increasingly being used in the evaluation of men with prostate cancer (PCa). It is therefore of increasing importance for imaging specialists to recognize potential pitfalls of this novel imaging technique. In this report, we describe a series of benign elastofibroma dorsi with uptake of the PSMA-targeted PET radiotracer ¹⁸F-DCFPyL. PATIENTS AND METHODS: We retrospectively analyzed the imaging data of 75 men with PCa who were consecutively imaged with ¹⁸F-DCFPyL PET/CT...
July 20, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28695370/erratum-to-repeatability-of-68-ga-dkfz11-psma-pet-scans-for-detecting-prostate-specific-membrane-antigen-positive-prostate-cancer
#19
Joseph R Osborne, Teja M Kalidindi, Blesida J Punzalan, Kishore Gangangari, Daniel E Spratt, Wolfgang A Weber, Steven M Larson, Naga Vara Kishore Pillarsetty
No abstract text is available yet for this article.
July 10, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28688023/-pet-ct-and-pet-mri-of-the-prostate-from-18-f-fdg-to-68-ga-psma
#20
REVIEW
K Knorr, M Eiber, T Maurer, H-J Wester, K Scheidhauer
CLINICAL/METHODICAL ISSUE: In the last few years nuclear medical diagnostics have experienced a unprecedented renaissance in the diagnostics of prostate cancer, due to the availability of hybrid imaging with positron emission tomography computed tomography (PET/CT), PET magnetic resonance imaging (PET/MRI) and single photon emission computed tomography (SPECT) CT as well as the development of prostate-specific radiopharmaceuticals. METHODICAL INNOVATIONS: The use of fluorodeoxyglucose (FDG), which has been successfully implemented for many years in PET diagnostics, is only helpful in dedifferentiated tumors due to the biological characteristics of prostate cancer...
July 7, 2017: Der Radiologe
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"